Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12612000423819
Ethics application status
Not yet submitted
Date submitted
2/04/2012
Date registered
16/04/2012
Date last updated
16/04/2012
Type of registration
Prospectively registered
Titles & IDs
Public title
Effects of Rapid Administration of Iron Polymaltose in Patients with Anaemia, Under General Anaesthesia for Routine Surgery. “The RAPID Trial”
Query!
Scientific title
An evaluation of adverse events and haemodynamic instability resulting from the rapid administration of iron polymaltose infusion in the operating department, in patients with iron deficiency anaemia under general anaesthesia for elective surgical procedures.
Query!
Secondary ID [1]
280267
0
ANZCA regKey 13/022
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
RAPID
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Peri-operative Anaemia
286215
0
Query!
Condition category
Condition code
Blood
286430
286430
0
0
Query!
Anaemia
Query!
Anaesthesiology
286503
286503
0
0
Query!
Other anaesthesiology
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
We aim to recruit 100 patients with iron deficiency anaemia or iron deficiency who are scheduled to undergo general anaesthesia for an elective surgical procedure. They will receive an intravenous iron polymaltose infusion over a 10 min period intra operatively, immediately following induction of anaesthesia during a period of haemodynamic stability. The dose given will be determined by the patients body weight and severity of anaemia (as dictated by a previously validated algorithm) up to a maximum dose of 1g. We will collect data on any adverse effects and change in blood pressure over this time and for 15 minutes following the infusion. Changes in blood pressure occuring as a result of the infusion will be compared to the decrease in blood pressure seen at the commencement of the patient's anaesthetic.
Query!
Intervention code [1]
284617
0
Treatment: Drugs
Query!
Comparator / control treatment
The patients will act as their own control; blood pressure changes secondary to anaesthetic will serve as control measurements against which changes secondary to the intervention are compared.
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
286873
0
Incidence of significant hypotension (i.e. systolic BP <80mmhg) and tachycardia (heart rate >100).
This will be measured using standard non-invasive blood pressure devices and a 3 lead ECG. All of this equipment is standardised anaesthetic monitoring in place for any general anaesthetic.
Query!
Assessment method [1]
286873
0
Query!
Timepoint [1]
286873
0
Haemodynamic data collection (BP and Heart Rate) at 5 minute intervals commencing before induction of anaesthesia and for 15 minutes following induction of anaesthesia.
Haemodynamic data collection (BP and Heart Rate) at 5 minute intervals commencing before commencement of iron polymaltose during the infusion (10 minutes) and for 15 minutes after completeion of the infusion.
Query!
Secondary outcome [1]
296876
0
Other adverse events.
Headache, nausea, flushing hypotension, muscle cramps.
Query!
Assessment method [1]
296876
0
Query!
Timepoint [1]
296876
0
Questionnaire at 2 hours post operatively. This is a general questionnaire asking about any other symptoms that may or may not be present. It is not intended to use a specific previously validated tool to assess this.
Query!
Eligibility
Key inclusion criteria
Iron deficiency anaemia defined as Hb < 120g/L if female or Hb < 130g/L if male with ferritin < 100 or Iron deficiency alone, defined as ferritin < 30
Elective surgery / procedure requiring general anaesthesia
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
100
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Pregnancy
Iron overload (haemochromatosis or haemosiderosis) or ferritin > 100
Clinically significant renal or liver disease
Chronic polyarthritis
Active infection
Allergy / intolerance to iron polymaltose
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Patients will be recruited from the routine anaesthetic preassesment clinic which they universlly attend preoperatively. Patients who are found to have iron deficiency anaemia at this preoperative visit will be approached to join the study. All patients wil receive the same treatment.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Not applicable
Query!
Masking / blinding
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
1/07/2012
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
100
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Funding & Sponsors
Funding source category [1]
285029
0
Charities/Societies/Foundations
Query!
Name [1]
285029
0
Australian and New Zealand College of Anaesthetists
Query!
Address [1]
285029
0
The Chief Executive Officer
Australian and New Zealand College of Anaesthetists
630 St Kilda Road
MELBOURNE VIC 3004
Query!
Country [1]
285029
0
Australia
Query!
Primary sponsor type
Hospital
Query!
Name
Fremantle Hospital
Query!
Address
Alma Street
Fremantle POBOX 480
West Australia
6160
Query!
Country
Australia
Query!
Secondary sponsor category [1]
283893
0
None
Query!
Name [1]
283893
0
Query!
Address [1]
283893
0
Query!
Country [1]
283893
0
Query!
Ethics approval
Ethics application status
Not yet submitted
Query!
Ethics committee name [1]
287034
0
Fremantle Hospital
Query!
Ethics committee address [1]
287034
0
Query!
Ethics committee country [1]
287034
0
Query!
Date submitted for ethics approval [1]
287034
0
01/05/2012
Query!
Approval date [1]
287034
0
Query!
Ethics approval number [1]
287034
0
Query!
Summary
Brief summary
Aim We aim to show that giving intravenous iron polymaltose over 10 minutes to patients who are under general anaesthesia is convenient, safe and not associated with a significant incidence of low blood pressure or other adverse effects. Background - Anaemia and iron deficiency are very common in surgical patients. A recent audit at KEMH, the tertiary womens hospital in WA, showed that 18% of women were anaemic prior to their gynaecological surgery. In patients undergoing surgery anaemia has been linked with an increased risk of needing a blood transfusion, slower recovery from surgery and an increase in postoperative complications. Patients often suffer from decreased energy, fatigue and poor ability to concentrate, all of which will affect their quality of life. - Iron polymaltose is an intravenous iron medication commonly used to correct anaemia and iron deficiency. It has been used in Australia for over 40 years, has a very good safety record and about 4-500 women a year receive iron polymaltose at KEMH currently. It is usually administered as a slow infusion over 2 - 3 hours in a general ward setting. Common adverse effects can include headache, nausea, flushing, low blood pressure and muscle cramps all of which are not as relevant to patients whilst they are under general anaesthesia. Serious adverse events such as anaphylaxis are extremely rare and are not related to the speed at which iron polymaltose is given. - Oral iron tablets are not effective in many patients for a number of reasons. It would labour intensive, expensive and inconvenient to bring all these patients back to a ward for a 1-2 hour infusion of iron polymaltose after surgery. Other intravenous iron preparations, with similar pharmacological properties, have been shown to be safe when given over similar short periods of time and we believe this will be the case with iron polymaltose too. Some anaesthetists (in Australia and NZ) have already administered iron polymaltose in this manner with no anecdotal reports of any problems, however we believe it warrants formal evaluation. Study Design and Methods We aim to recruit 100 patients with iron deficiency anaemia or iron deficiency who are scheduled to undergo general anaesthesia for an elective surgical procedure. Routine care will be unaffected and they will receive general anaesthesia as they would if they were not involved in this trial. Following commencement of surgery and during a period of haemodynamic stability (as assessed by the responsible anaesthetist), they will receive an iron polymaltose infusion over a 10 min period and we will collect data on any adverse effects and change in blood pressure over this time. In order to assess the haemodynamic impact of the infusion, any changes in blood pressure will be compared to the decrease in blood pressure seen at the start of the anaesthetic. Outcomes Primary outcome will be the incidence of significant low blood pressure following the administration of iron polymaltose (definition = systolic BP less than 80mmHg or blood pressure treatment required). Secondary outcomes, will be the incidence of all adverse effects as ascertained by questionnaire 2 hours after surgery and changes in blood markers of iron deficiency. Potential Benefits / Ethical Issues The current drug manufacturers product information sheet, recommends a slow infusion of iron polymaltose over approximately 4.5 hours, however most WA hospitals already administer iron polymaltose over a shorter periods of time, with no serious problems. We believe that if we demonstrate this technique of administration is safe it may lead to more effective & widespread treatment of iron deficiency and anaemia in surgical patients
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
34014
0
Query!
Address
34014
0
Query!
Country
34014
0
Query!
Phone
34014
0
Query!
Fax
34014
0
Query!
Email
34014
0
Query!
Contact person for public queries
Name
17261
0
Dr Matthew Harper
Query!
Address
17261
0
Department of Anaesthesia
Fremantle Hospital
Level 5 Block
Alma Street
Fremantle
Western Australia 6160
Query!
Country
17261
0
Australia
Query!
Phone
17261
0
+61 450 832228
Query!
Fax
17261
0
Query!
Email
17261
0
[email protected]
Query!
Contact person for scientific queries
Name
8189
0
Dr Matthew Harper
Query!
Address
8189
0
Department of Anaesthesia
Fremantle Hospital
Level 5 Block
Alma Street
Fremantle
Western Australia 6160
Query!
Country
8189
0
Australia
Query!
Phone
8189
0
+61 450 832228
Query!
Fax
8189
0
Query!
Email
8189
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF